X0306 4 2023-03-13 0 0001402479 MedAvail Holdings, Inc. MDVL 0001832110 ABG WTT-MedAvail Ltd UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG K3 HONG KONG 0 0 1 0 0001808684 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG K3 HONG KONG 0 0 1 0 0001832109 ABG-WTT Global Life Science Capital Partners GP, L.P. UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG K3 HONG KONG 0 0 1 0 0001832108 ABG-WTT Global Life Science Capital Partners GP Ltd UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG K3 HONG KONG 0 0 1 0 0001832106 ABG Management Ltd. UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG K3 HONG KONG 0 0 1 0 0001668029 Yu Fan UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG K3 HONG KONG 0 0 1 0 0001831963 Ally Bridge MedAlpha Master Fund L.P. 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 0 0 1 0 0001822947 Ally Bridge Group (NY) LLC 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 0 0 1 0 Pre-Funded Warrant (Right to Buy) 0.001 2023-03-13 4 P 0 6818181 0.3212 A 2023-03-13 Common Stock 6818181 6818181 I See footnote Pre-Funded Warrant (Right to Buy) 0.001 2023-03-13 4 P 0 965130 0.3212 A 2023-03-13 Common Stock 965130 965130 I See footnote Prior to the Issuer receiving certain required approval of the Issuer's stockholders (the "Requisite Stockholder Approval"), the Pre-Funded Warrant holders may only exercise up to the product of (i) the holder's pro rata portion of the Pre-Funded Warrants and (ii) 16,025,925, which is the number of shares equal to 19.99% of the Issuer's Common Stock outstanding on March 9, 2023. The Pre-Funded Warrants do not expire. These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner By: /s/ Fan Yu, Director 2023-03-15 ABG-WTT Global Life Science Capital Partners GP, L.P. By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner By: /s/ Fan Yu, Director 2023-03-15 ABG-WTT Global Life Science Capital Partners GP Limited By: /s/ Fan Yu, Director 2023-03-15 Ally Bridge MedAlpha Master Fund L.P. By: Ally Bridge MedAlpha General Partner L.P., its general partner By: Ally Bridge MedAlpha GP, LLC, its general partner By: /s/ Fan Yu, Manager 2023-03-15 Ally Bridge Group (NY) LLC By: ABG Management Ltd., its managing member By: /s/ Fan Yu, Director 2023-03-15 ABG Management Ltd. By: /s/ Fan Yu, Director 2023-03-15 ABG WTT-MedAvail Limited By: /s/ Charles Chon, Director 2023-03-15 /s/ Fan Yu 2023-03-15